The perfect villain
Few acronyms carry as much symbolic weight in sport as EPO. Recombinant erythropoietin (rHuEPO) became synonymous with cheating in the era of Lance Armstrong, the Festina scandals and the peloton that climbed mountains with absurd hematocrits. The physiological logic is impeccable: more EPO stimulates the marrow to produce more red blood cells, the blood carries more oxygen and VO2max rises. Nobody serious disputes that.
That is why it caused discomfort when a Dutch group published data suggesting that, in a real road race, cyclists doped with EPO were no faster than those who took salt water. The provocative question left hanging was: what if EPO's real-world performance gain has been chronically overestimated?
What the trial actually found
The central work is by Heuberger and colleagues, published in Lancet Haematology in 2017. It was a double-blind, randomized, placebo-controlled trial with 48 well-trained amateur cyclists, men aged 18 to 50. Half received epoetin beta (an average of 6000 IU per week) for 8 weeks, the other half received saline solution. At the end, everyone faced a climb up Mont Ventoux.
In other words: the doped group was, on average, 17 seconds slower on the road, a difference without statistical significance. The submaximal test, closer to the demands of a long race, also did not separate the groups. The authors' conclusion was surgical: EPO improved a maximal laboratory effort test, but not the outcomes most relevant to a race.
Why VO2max is not the same as winning
Here lives the nuance. In an earlier review by the same group, in the British Journal of Clinical Pharmacology (2013), the researchers examined 13 studies on EPO and endurance. The problem they pointed out is methodological: almost all measured only VO2max, not performance in a real race.
The physics of racing explains the mismatch. In a long road race, the cyclist almost never pedals at their VO2max. Most of the time is spent at submaximal intensity, governed by factors such as pedaling economy, lactate threshold and strategy. An engine with a higher ceiling does not help if you rarely touch the ceiling.
The other side: the critics are right too
It would be irresponsible to read this as EPO does not work. The authors themselves and the scientific community pointed out important limits.
- Amateur sample, not professional. Researchers cannot dope elite athletes without exposing them to bans. The study's lead author, Jules Heuberger, admitted that the question remains whether the findings hold for professional cyclists.
- Short duration. A single climb does not reproduce the accumulated fatigue of a three-week Grand Tour, where many suspect EPO's true gain lies in recovery between stages, not in an isolated time trial.
- Institutional skepticism. Olivier Rabin, scientific director of the World Anti-Doping Agency, summed up the reaction: the scientific community will receive this with great skepticism.
The honest reading is not that the substance is harmless. It is that the magnitude of the gain in real race performance may have been inflated by culture, by the placebo effect and by the direct extrapolation of laboratory VO2max to the result on the road.
The history does not lie
The human context is inseparable from the numbers. Lance Armstrong received a lifetime ban from USADA, was stripped of his seven Tour de France titles and confessed to Oprah Winfrey, in January 2013, the systematic use of EPO, transfusions and other substances. Bjarne Riis, winner of the 1996 Tour and nicknamed Mr. 60 percent for his supposed hematocrit, confessed in 2007 to using EPO between 1993 and 1998.
Entire generations risked their health convinced of a benefit that the best available evidence suggests was, at least in part, overestimated. And the cost was real: the 2013 review points to increased risk of thrombotic events and other serious dangers, classifying use as a negative risk-benefit relationship.
What stays
The EPO controversy is a rare case where the provocative headline and the scientific nuance coexist. EPO raises VO2max, there is no doubt about that. But turning that physiological gain into seconds on a finish line is far less automatic than decades of mythology suggested. Clean science does not elect easy heroes or villains: it measures, doubts and measures again.
